Application of monocaprylic acid glycerol in preparing obesity therapeutic drugs or functional foods
By regulating the expression of basal metabolism-related genes with monoglyceride capric acid, the problem of high-fat diet-induced obesity is solved, significantly reducing weight and improving glycolipid metabolism, providing a safe and effective obesity treatment or auxiliary treatment method.
Patent Information
- Application Number
- CN202410935517.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-12
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-12
AI Technical Summary
The prior art is difficult to effectively treat or assist in the treatment of obesity, especially in cases of obesity induced by a high-fat diet, and lacks safe and effective food-grade substances for regulating basal metabolism and weight management.
Monoglyceride capric acid is used as the main active ingredient, and by regulating the expression of basal metabolism-related genes, it significantly reduces weight, increases the heat production of brown fat, and improves glycolipid metabolism. It is used to prepare drugs or functional foods for the treatment or auxiliary treatment of obesity.
Monoglyceride capric acid significantly reduces body weight, reduces triglycerides and low-density lipoprotein cholesterol levels caused by high-fat diets, increases energy consumption, improves glycolipid metabolism, and has good safety and application prospects.
Smart Images

Figure CN118453565B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to application of capric monoglyceride in preparing medicines for treating obesity or functional foods for controlling body weight. Background Art
[0002] Medium-chain fatty acids are a type of carboxylic acid with a carbon chain length of 8-12 carbons. They can combine with glycerol to form medium-chain glycerides, including monoglycerides, diglycerides, and triglycerides, and can also exist in a free state. Medium-chain fatty acids have physiological functions such as antibacterial, anti-inflammatory, and antioxidant, which can enhance immunity, protect intestinal health, and prevent infection and inflammation.
[0003] The compound formed by the esterification of one medium-chain fatty acid molecule and one glycerol molecule is medium-chain fatty acid monoglyceride, which is an important non-ionic surfactant with emulsification, lubrication, antibacterial, anti-inflammatory, and antioxidant properties. It is widely used in food, cosmetics, medicine and other fields. Like medium-chain fatty acids, medium-chain fatty acid monoglyceride is digested and absorbed quickly in the body. It does not require the participation of bile and pancreatic lipase, and can directly enter the liver through the portal vein to quickly provide energy (Research Progress and Application Status of Medium-Chain Fatty Acids. China Food Additives, 2022, 12: 50-55.).
[0004] In terms of metabolism in the body, medium-chain fatty acid monoglycerides can promote the production of ketone bodies, which are energy substances that can replace glucose. They have certain therapeutic effects on patients with diabetes, epilepsy, Alzheimer's disease, etc. (Supplementation of regular diet with medium-chain triglycerides for procognitive effects: A narrative review. Front Nutr, 2022, 15:9:934497.).
[0005] In terms of physiological functions, medium-chain fatty acid monoglycerides have antibacterial, anti-inflammatory, antioxidant and other physiological functions, which can enhance immunity, protect intestinal health, and prevent infection and inflammation.
[0006] Capric acid monoglyceride is a type of medium-chain fatty acid monoglyceride. It exists naturally in palm kernel oil and camphor seed oil. It is a white solid powder. It has good antibacterial and antiviral effects. It also has the unique emulsifying properties of medium-chain fatty acid monoglyceride and has application prospects as a food additive or functional food. Summary of the invention
[0007] The purpose of the present invention is to provide a food-grade substance that has the function of regulating the basal metabolism of humans or animals, and to apply the substance to the preparation of drugs for treating or assisting in the treatment of obesity and related diseases or to the preparation of health foods for weight loss.
[0008] To achieve the above object, the present invention adopts the following technical solution:
[0009] The invention provides application of capric acid monoglyceride in preparing medicine for preventing or treating obesity or preparing functional food for reducing body weight.
[0010] The present invention found that monocapric acid glyceryl has positive benefits in regulating basal metabolism in a simulated high-fat diet animal model, and the effects of regulating basal metabolism mainly include weight regulation, heat production, blood sugar and blood lipids, and the expression of genes related to energy metabolism in tissues and organs. Under the high-fat diet model, monocapric acid glyceryl can significantly reduce body weight and alleviate obesity.
[0011] Therefore, monocaprin can be used to prepare compositions for supporting weight management, promoting weight loss and / or treating obesity.
[0012] Furthermore, the obesity includes obesity induced by a high-fat diet. The obesity is a group of common metabolic diseases. When the body consumes more calories than it consumes, the excess calories are stored in the body in the form of fat, and the amount exceeds the normal physiological requirement. When it reaches a certain value, it develops into obesity.
[0013] Furthermore, the symptoms of obesity include abnormal blood lipids and blood sugar in the body.
[0014] Furthermore, the manifestation of obesity is abnormal increase in total cholesterol, triglyceride, low-density lipoprotein cholesterol and glucose in serum. The present invention shows that monocapric acid glycerol can significantly reduce the high levels of triglyceride, low-density lipoprotein cholesterol and glucose caused by high-fat diet after intervention, and improve sugar and lipid metabolism.
[0015] Therefore, the present invention also provides the use of capric acid monoglyceride in preparing functional food for assisting in lowering blood lipids.
[0016] The present invention found that monocaprylic acid glycerol intervention can increase the heat production of brown fat, increase body temperature within the normal range, and increase energy consumption. Mechanism studies have shown that monocaprylic acid glycerol increases energy consumption by positively regulating the expression of energy metabolism-related genes in brown fat, liver, and muscle (skeletal muscle) tissue. Furthermore, the energy metabolism-related genes include the gene encoding uncoupling protein 1 in brown fat. UCP1 , PR domain zinc finger protein 16 encoding gene PRDM16 ; Glucokinase encoding gene in liver GCK, Stearoyl-CoA desaturase 1 encoding gene SCD1 ; Muscle peroxisome proliferator-activated receptor gamma coactivator 1 encoding gene PGC-1α , glucose transporter 4 encoding gene GLUT4 .
[0017] Monocapric acid glyceride exists naturally in edible oils and has high biological safety. It is expected to be developed into a drug for the treatment or auxiliary treatment of obesity, or into a functional food for assisting in lowering blood lipids, or for weight loss or weight management.
[0018] Specifically, the present invention provides a pharmaceutical composition for treating or assisting in the treatment of obesity, comprising an effective dose of monocaprylin and a pharmaceutically acceptable carrier.
[0019] The pharmaceutical composition is prepared by adding capric acid monoglyceride as the main active ingredient and a pharmaceutically acceptable carrier, and can be prepared according to the preparation method recorded in pharmacy. The preparation form of the drug can be, but is not limited to, an oral preparation. The specific dosage is adjusted according to the type of disease, the degree of disease, age and the purpose of administration.
[0020] In the mouse model, the effective dose of monocaprylic acid glycerol was 1600 mg / kg.bw / d without obvious toxic side effects.
[0021] Specifically, the present invention provides a functional food for weight loss, comprising capric acid monoglyceride and a food science acceptable auxiliary material. The present invention uses capric acid monoglyceride as an active ingredient to prepare a corresponding functional food, which can also be added to food or beverages in the form of a food additive to promote weight loss of the user.
[0022] Terminology Note:
[0023] The term "comprising" is an open expression, that is, it includes the contents specified in the present invention but does not exclude other contents.
[0024] The term "treating" refers in some embodiments to ameliorating a disease or condition (i.e., slowing or arresting or alleviating the development of a disease or at least one clinical symptom thereof). In other embodiments, it refers to alleviating or improving at least one physical parameter, including physical parameters that may not be perceived by the subject. In other embodiments, it refers to regulating a disease or condition physically (e.g., stabilizing a perceptible symptom) or physiologically (e.g., stabilizing a physical parameter), or both. In other embodiments, it refers to preventing or delaying the onset, onset, or worsening of a disease or condition.
[0025] The term "effective dose" refers to an amount of a compound that is sufficient to be effective in treating a disease when administered to a subject. The effective dose may vary with the severity of the disease, and the physical condition, age, weight, sex, etc. of the subject to be treated.
[0026] The term "pharmaceutically or edible acceptable carrier / excipient" refers to any preparation or carrier medium that can deliver an effective dose of the active substance of the present invention without interfering with the biological activity of the active substance and having no toxic side effects on the host or subject.
[0027] The present invention has the following beneficial effects:
[0028] The present invention discloses for the first time that monoglyceride of capric acid has positive benefits in regulating basal metabolism. For people or animals on a high-fat diet, monoglyceride of capric acid can significantly reduce body weight, reduce body fat, and alleviate obesity; and increase the heat production of brown fat, increase body temperature within a normal range, and increase energy consumption. Moreover, monoglyceride of capric acid is an edible substance with high safety. Therefore, it can be used to prepare drugs for treating obesity or to prepare functional foods for assisting in lowering blood lipids or for weight management, and has good application prospects. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1 This is a technical roadmap for verifying the function of monocaprylic acid glycerol (GMD) under the high-fat dietary model in Example 1.
[0030] Figure 2 The figure shows the changes in body weight, energy intake and body temperature of mice fed with a high-fat diet for 16 weeks in Example 1, where A is the change in total weight gain percentage; B is the total weight gain at week 16; C is the total energy intake; and D is the body temperature at week 15. In the figure, # indicates a significant analysis with the NCD group, * indicates a significant analysis with the HFD group, $ indicates a significant analysis with the GMD150 group, & indicates a significant analysis with the GMD800 group, ### represents p<0.001, ** represents p<0.01, $$$ represents p<0.001, and &&& represents p<0.001.
[0031] Figure 3The changes in serum indicators obtained by mice after feeding in the high-fat diet mode in Example 1, wherein A is the content of total cholesterol in serum; B is the content of triglycerides in serum; C is the content of low-density lipoprotein cholesterol in serum; and D is the content of glucose in serum. In the figure, # indicates a significant analysis with the NCD group, * indicates a significant analysis with the HFD group, $ indicates a significant analysis with the GMD150 group, & indicates a significant analysis with the GMD800 group, ## represents p<0.01, ### represents p<0.001, * represents p<0.05, *** represents p<0.001, $$$ represents p<0.001, & represents p<0.05, && represents p<0.01.
[0032] Figure 4 The gene expression in the tissues of mice after feeding under the high-fat diet model in Example 1, where A is the uncoupling protein 1 in brown fat ( UCP1 ) expression in brown fat; B is the expression of PR domain zinc finger protein 16 ( PRDM16 ) expression; C is the expression of glucose kinase in liver ( GCK ) expression; D is the expression of stearoyl-CoA desaturase 1 ( SCD1 ) expression; E is the expression of peroxisome proliferator-activated receptor γ coactivator 1 ( PGC-1α ) expression; F is the expression of glucose transporter 4 in muscle ( GLUT4 ). In the figure, # indicates significant analysis with the NCD group, * indicates significant analysis with the HFD group, $ indicates significant analysis with the GMD150 group, & indicates significant analysis with the GMD800 group, # represents p<0.05, ## represents p<0.01, ### represents p<0.001, * represents p<0.05, *** represents p<0.001, $$ represents p<0.01, $$$ represents p<0.001, & represents p<0.05, &&& represents p<0.001.
[0033] Figure 5 The effects of three medium-chain fatty acid monoglycerides on the body weight and energy intake of mice fed a high-fat diet in Example 2, where A is the total weight gain percentage curve within 16 weeks of feeding; B is the total weight gain of mice at week 16; and C is the average daily energy intake of mice. In the figure, # indicates a significant analysis with the low-fat control group (NCD), * indicates a significant analysis with the high-fat control group (HFD), $ indicates a significant analysis with the GMC1600 group, * represents p < 0.05, *** represents p < 0.001, ## represents p < 0.01, ### represents p < 0.001, and $$ represents p < 0.01. DETAILED DESCRIPTION
[0034] The present invention will be further described below in conjunction with specific embodiments. The following embodiments are only used to illustrate the present invention and are not intended to limit the scope of application of the present invention. Without departing from the spirit and essence of the present invention, modifications or replacements made to the inventive method, steps or conditions all belong to the scope of the present invention.
[0035] The test methods used in the following examples are conventional methods unless otherwise specified; the materials and reagents used are commercially available, including capric monoglyceride CAS: 26402-22-2, lauric monoglyceride CAS: 40738-26-9, and caprylic monoglyceride CAS: 26402-26-6.
[0036] Example 1: Effects of capric monoglyceride (GMD) on mice on a high-fat diet
[0037] 1. Select 60 4-5 week old C57BL / 6 male mice and raise them in the SPF rodent breeding room of the Animal Experiment Center of Zhejiang Chinese Medical University. After 7 days of pre-feeding, the 60 mice were randomly divided into 5 groups and continued to be fed with ordinary feed or high-fat feed for 16 weeks. The grouping scheme is as follows:
[0038] (1) Normal diet control group (NCD), 12 mice in each group, 4 mice in each cage, 3 cages in total;
[0039] (2) High-fat diet control group (HFD), 12 mice in each group, 4 mice in each cage, for a total of 3 cages;
[0040] (3) 150 mg / kg GMD + high-fat diet group (GMD150), 12 mice in each group, 4 mice in each cage, for a total of 3 cages;
[0041] (4) 800 mg / kg GMD + high-fat diet group (GMD800), 12 mice in each group, 4 mice in each cage, for a total of 3 cages;
[0042] (5) 1600 mg / kg GMD + high-fat diet group (GMD1600), 12 mice in each group, 4 mice in each cage, for a total of 3 cages.
[0043] The weight and food intake of mice were recorded regularly every week, and the body temperature of mice was measured using an infrared thermometer at the 15th week; at the end of the experiment, the serum, liver, skeletal muscle, and brown fat of mice were collected and frozen at -80°C. Figure 1 The feed composition of each group is shown in Table 1.
[0044] Table 1. Composition of experimental diets
[0045] Composition (g / 100 g feed) NCD HFD GMD150 GMD800 GMD1600 Casein 18.96 23.31 23.31 23.31 23.31 L-Cystine 0.28 0.35 0.35 0.35 0.35 Corn starch 29.86 8.48 8.48 8.48 8.48 Maltodextrin 3.32 11.65 11.65 11.65 11.65 sucrose 33.17 20.14 20.14 20.14 20.14 Cellulose 4.74 5.83 5.83 5.83 5.83 Soybean Oil 2.37 2.91 2.91 2.91 2.91 lard 1.90 20.68 20.665 20.6 20.52 GMD 0 0 0.015 0.08 0.16 Mineral mixture 2.68 3.31 3.31 3.31 3.31 1 Potassium Citrate Water 1.56 1.92 1.92 1.92 1.92 Vitamin Mix 0.95 1.16 1.16 1.16 1.16 Choline Bitartrate 0.19 0.23 0.23 0.23 0.23 Calorie supplement (kcal %) protein 20 20 20 20 20 carbohydrate 70 35 35 35 35 Fat 10 45 45 45 45 Total calories (kcal / 100 g feed) 385 473 473 473 473
[0046] 2. Effects of capric monoglyceride (GMD) on body weight, food intake, and body temperature of mice under high-fat diet
[0047] The results are as follows Figure 2 As shown in the figure, after 16 weeks of high-fat diet, the body weight of mice in the HFD group increased significantly compared with the NCD group; compared with the HFD group, low and medium doses of GMD slightly increased the body weight of mice ( Figure 2 However, when the dose was increased to 1600 mg / kg, GMD significantly reduced the total weight gain of mice, and there was no significant difference in total energy intake among the groups ( Figure 2 At week 15, 1600 mg / kg of GMD significantly increased the body temperature of mice compared with the HFD group ( Figure 2 D in.
[0048] 3. Effects of capric monoglyceride (GMD) on serum parameters of mice under high-fat diet
[0049] Long-term high-fat diet can induce obesity, and in severe cases, it can even cause abnormal increases in blood lipids and blood sugar. The total cholesterol content, triglyceride content, low-density lipoprotein cholesterol content, and glucose content in the serum of mice under the high-fat diet model were measured using the kit from Nanjing Jiancheng Bioengineering Institute.
[0050] The results are as follows Figure 3 As shown, compared with the NCD group, the levels of total cholesterol, triglycerides, low-density lipoprotein cholesterol, and glucose in the serum of mice in the HFD group were significantly increased; compared with the HFD group, 1600 mg / kg of GMD reduced the level of total cholesterol in serum, and significantly reduced the levels of triglycerides, low-density lipoprotein cholesterol, and glucose in serum.
[0051] The results show that GMD can significantly improve the glucose and lipid metabolism of mice and affect the basal metabolism of mice.
[0052] 4. Effects of capric monoglyceride (GMD) on gene expression in mice under high-fat diet
[0053] Real-time fluorescence quantitative PCR was used to detect gene expression in the liver: RNA in the liver was extracted using Trizol, and the concentration and purity of RNA were determined using a Nanodrop ND-2000 spectrophotometer. The extracted RNA was then reverse transcribed into cDNA using a reverse transcription kit from Nanjing Novozymes, and SYBR fluorescent dye from Novozymes was used on a LightCycler480 instrument to detect uncoupling protein 1 in brown fat ( UCP1 )、PR domain zinc finger protein 16( PRDM16 ), glucokinase in liver ( GCK )、stearoyl-CoA desaturase 1( SCD1 ), peroxisome proliferator-activated receptor gamma coactivator 1 ( PGC-1α )、Glucose transporter 4( GLUT4 )’s expression.
[0054] Table 2. Primer list
[0055] Forward primer (5'-3') Reverse primer (5'-3') AACATTCAATCCCGGGAGAATA GAAACTTTCTTCCGGTCGTAAG AGGCTTCCAGTACCATTAGGT CTGAGTGAGGCAAAGCTGATTT ATCGCCAACAGCGAGATGAA GATCTCAGGCCGTTTGTCCA TCCCTGTAAGGCACGAAGAC ACGATGTTGTTCCCTTCTGC GGCCTAACTCCTCCCACAAC AGGGATGACCGAAGTGCTTG AACACTCAACCAACTGGCCA CACCGAGACCAACGTGAAGA
[0056] Brown fat is brown fat tissue in the body. It is the main source of non-shivering heat production in mammals and plays an important role in maintaining the body temperature and energy balance of animals. UCP1 is an important regulator in body temperature regulation and energy metabolism, and is mainly expressed in adipose tissue. PRDM16 is a downstream gene of UCP1 and is also a key gene in regulating energy metabolism of adipose tissue in the body.
[0057] Figure 4 Results A and B in Figure 1 show that 1600 mg / kg of GMD can increase brown fat UCP1 expression, and at the same time, can significantly increase PRDM16 Express.
[0058] The liver is the main organ responsible for metabolism in the body. Most glycolipids and energy need to be broken down and synthesized in the liver. GCK is the first rate-limiting enzyme in the glucose metabolism process. It can convert glucose into glucose-6-phosphate, which is the first step in glycolysis and glycogen synthesis. GCK can also act as a glucose receptor to regulate insulin secretion and energy balance. SCD1 is the rate-limiting enzyme required by the body to produce monounsaturated fatty acids from saturated fatty acids and is key to lipid metabolism.
[0059] Figure 4 The results in C and D showed that 1600 mg / kg of GMD could significantly increase the liver function of mice fed a high-fat diet. GCK Gene expression, while reducing SCD1 Gene expression.
[0060] Muscle tissue is also the main organ of energy metabolism in the body, storing and consuming a large amount of glycogen. PGC-1α is a transcriptional coactivator that can bind to a variety of nuclear receptors to regulate the expression of genes related to glucose and lipid metabolism, and at the same time increase the expression of glucose transporter-4 ( GLUT4 ) expression, thereby enhancing glucose uptake and utilization and lowering blood sugar levels.
[0061] Figure 4 Results in Figures E and F show that GMD can significantly increase the muscle tissue (skeletal muscle) of mice on a high-fat diet. PGC-1αGene expression, while increasing GLUT4 Gene expression.
[0062] The gene expression results of mice under a high-fat diet model showed that GMD increased the expression of energy metabolism-related genes in brown fat, liver and skeletal muscle of mice, among which 1600 mg / kg GMD had a more significant effect.
[0063] Example 2: Effects of three medium-chain fatty acid monoglycerides on body weight and energy intake in mice fed a high-fat diet
[0064] 60 4-week-old healthy male C57BL / 6 mice (SPF) from Shanghai Slake Laboratory Animal Co., Ltd. were selected as experimental subjects. After 2 weeks of pre-feeding, all mice were randomly divided into 5 experimental groups, each of which was divided into 3 cages with 4 mice in each cage, and the mice were raised for 16 weeks. The detailed groups are as follows:
[0065] Low-fat control group (NCD): fed with normal feed and free access to water every day;
[0066] High-fat control group (HFD): fed with high-fat diet and free access to water every day;
[0067] Caprylic monoglyceride experimental group (GMC): fed with high-fat GMC feed (containing 1600 mg / kg of GMC), with free access to water every day;
[0068] Capric monoglyceride experimental group (GMD): fed with high-fat GMD feed (containing 1600 mg / kg of GMD), with free access to water every day;
[0069] Monolaurin experimental group (GML): fed with high-fat GML feed (containing 1600 mg / kg of GML), with free access to water every day.
[0070] The body weight and food intake of mice were recorded regularly every week. The feed composition is shown in Table 3.
[0071] Table 3. Composition of experimental feeds
[0072] Composition (g / 100 g feed) NCD HFD GMC1600 GMD1600 GML1600 Casein 18.96 23.31 23.31 23.31 23.31 L-Cystine 0.28 0.35 0.35 0.35 0.35 Corn starch 29.86 8.48 8.48 8.48 8.48 Maltodextrin 3.32 11.65 11.65 11.65 11.65 sucrose 33.17 20.14 20.14 20.14 20.14 Cellulose 4.74 5.83 5.83 5.83 5.83 Soybean Oil 2.37 2.91 2.91 2.91 2.91 lard 1.90 20.68 20.52 20.52 20.52 GMC 0 0 0.16 0 0 GMD 0 0 0 0.16 0 GML 0 0 0 0 0.16 Mineral mixture 2.68 3.31 3.31 3.31 3.31 1 Potassium Citrate Water 1.56 1.92 1.92 1.92 1.92 Vitamin Mix 0.95 1.16 1.16 1.16 1.16 Choline Bitartrate 0.19 0.23 0.23 0.23 0.23 Calorie supplement (kcal %) protein 20 20 20 20 20 carbohydrate 70 35 35 35 35 Fat 10 45 45 45 45 Total calories (kcal / 100 g feed) 385 473 473 473 473
[0073] The results are as follows Figure 5 As shown, both GMD and GML can significantly reduce the body weight of mice fed a high-fat diet, but GMD is the most effective in reducing the body weight of mice, which is better than GML.
Claims
1. Use of capric acid monoglyceride in preparing a drug for preventing or treating obesity or a functional food for assisting weight loss or assisting in lowering blood lipids, characterized in that: The obesity is induced by a high-fat diet, and its manifestations include abnormal increases in blood lipids and blood sugar in the body.
2. The use according to claim 1, characterized in that The manifestations of obesity include abnormal increases in the total cholesterol level, triglyceride level, low-density lipoprotein cholesterol level, and glucose level in serum.
3. The use according to claim 1, characterized in that Monocaprylic acid monoglyceride increases energy expenditure by positively regulating the expression of energy metabolism-related genes in brown fat, liver, and muscle tissue.
